Bacterial Over-expression of Functionally Active Human CT2 (SLC22A16) Carnitine Transporter

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 May 24

PMID 35608746

Authors

Michele Galluccio

Tiziano Mazza

Mariafrancesca Scalise

Maria Chiara Sarubbi

Cesare Indiveri

Affiliations

Soon will be listed here.

Abstract

Background: Escherichia coli is a widely used tool for the over-expression of human proteins for studying structure and function. The toxicity of human proteins for E. coli often hampers the expression. This study aims to find conditions for the expression of a membrane transporter known as the carnitine transporter CT2. The knowledge on this transporter is scarce, thus obtaining the recombinant protein is very important for further studies.

Methods And Results: The cDNAs coding for human CT2 (hCT2) was cloned in the pH6EX3 vector and different transformed E. coli strains were cultured in absence or in presence of glucose. hCT2 expression was obtained. The protein was purified and reconstituted into proteoliposomes in a functionally active state.

Conclusions: Using the appropriate IPTG concentration, together with the addition of glucose, hCT2 has been expressed in E. coli. The protein is active and shows capacity to transport carnitine in proteoliposomes. The results have a great interest in basic biochemistry of membrane transporters and applications to human health since hCT2 is involved in human pathology.

Citing Articles

The Human OCTN Sub-Family: Gene and Protein Structure, Expression, and Regulation.

Galluccio M, Tripicchio M, Pochini L Int J Mol Sci. 2024; 25(16).

PMID: 39201429 PMC: 11354717. DOI: 10.3390/ijms25168743.

Involvement of mammalian SoLute Carriers (SLC) in the traffic of polyamines.

Pochini L Front Mol Biosci. 2024; 11:1452184.

PMID: 39130372 PMC: 11310933. DOI: 10.3389/fmolb.2024.1452184.

Over-Production of the Human SLC7A10 in and Functional Assay in Proteoliposomes.

Galluccio M, Mazza T, Scalise M, Tripicchio M, Scarpelli M, Tolomeo M Int J Mol Sci. 2024; 25(1).

PMID: 38203703 PMC: 10779382. DOI: 10.3390/ijms25010536.

Production of recombinant human xCT (SLC7A11) and reconstitution in proteoliposomes for functional studies.

Galluccio M, Scalise M, Pappacoda G, Scarpelli M, Bonanomi M, Gaglio D Front Physiol. 2022; 13:993626.

PMID: 36148304 PMC: 9485625. DOI: 10.3389/fphys.2022.993626.

Heterologous (Over) Expression of Human SoLute Carrier (SLC) in Yeast: A Well-Recognized Tool for Human Transporter Function/Structure Studies.

Pochini L, Galluccio M Life (Basel). 2022; 12(8).

PMID: 36013385 PMC: 9410066. DOI: 10.3390/life12081206.

References

Bieber L . Carnitine. Annu Rev Biochem. 1988; 57:261-83. DOI: 10.1146/annurev.bi.57.070188.001401. View

Huizing M, Iacobazzi V, IJlst L, Savelkoul P, Ruitenbeek W, van den Heuvel L . Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient. Am J Hum Genet. 1997; 61(6):1239-45. PMC: 1716087. DOI: 10.1086/301628. View

Pochini L, Scalise M, Galluccio M, Indiveri C . OCTN cation transporters in health and disease: role as drug targets and assay development. J Biomol Screen. 2013; 18(8):851-67. DOI: 10.1177/1087057113493006. View

Koepsell H, Lips K, Volk C . Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007; 24(7):1227-51. DOI: 10.1007/s11095-007-9254-z. View

Pochini L, Galluccio M, Scalise M, Console L, Indiveri C . OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics. SLAS Discov. 2018; 24(2):89-110. DOI: 10.1177/2472555218812821. View

Enomoto A, Wempe M, Tsuchida H, Shin H, Cha S, Anzai N . Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002; 277(39):36262-71. DOI: 10.1074/jbc.M203883200. View

Gong S, Lu X, Xu Y, Swiderski C, Jordan C, Moscow J . Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol. 2002; 30(10):1162-9. DOI: 10.1016/s0301-472x(02)00901-3. View

Sato N, Ito K, Onogawa T, Akahira J, Unno M, Abe T . Expression of organic cation transporter SLC22A16 in human endometria. Int J Gynecol Pathol. 2007; 26(1):53-60. DOI: 10.1097/01.pgp.0000225845.67245.b3. View

Carracedo A, Cantley L, Pandolfi P . Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013; 13(4):227-32. PMC: 3766957. DOI: 10.1038/nrc3483. View

10.

Wu Y, Hurren R, MacLean N, Gronda M, Jitkova Y, Sukhai M . Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis. 2015; 20(8):1099-108. DOI: 10.1007/s10495-015-1137-x. View

11.

Zhao W, Wang Y, Yue X . SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer. Future Oncol. 2018; 14(21):2139-2148. DOI: 10.2217/fon-2018-0207. View

12.

Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T . Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun. 2005; 333(3):754-62. DOI: 10.1016/j.bbrc.2005.05.174. View

13.

Novak A, Asmann Y, Maurer M, Wang C, Slager S, Hodge L . Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J. 2015; 5:e346. PMC: 4558593. DOI: 10.1038/bcj.2015.69. View

14.

Bray J, Sludden J, Griffin M, Cole M, Verrill M, Jamieson D . Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010; 102(6):1003-9. PMC: 2844036. DOI: 10.1038/sj.bjc.6605587. View

15.

Lal S, Wong Z, Jada S, Xiang X, Chen Shu X, Ang P . Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 2007; 8(6):567-75. DOI: 10.2217/14622416.8.6.567. View

16.

Faraji A, Dehghan Manshadi H, Mobaraki M, Zare M, Houshmand M . Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. PLoS One. 2016; 11(12):e0168519. PMC: 5201260. DOI: 10.1371/journal.pone.0168519. View

17.

Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O . Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol. 2015; 75(5):985-91. DOI: 10.1007/s00280-015-2723-x. View

18.

Aouida M, Poulin R, Ramotar D . The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2009; 285(9):6275-84. PMC: 2825423. DOI: 10.1074/jbc.M109.046151. View

19.

Scalise M, Console L, Galluccio M, Pochini L, Indiveri C . Chemical Targeting of Membrane Transporters: Insights into Structure/Function Relationships. ACS Omega. 2020; 5(5):2069-2080. PMC: 7016923. DOI: 10.1021/acsomega.9b04078. View

20.

Cosco J, Scalise M, Colas C, Galluccio M, Martini R, Rovella F . ATP modulates SLC7A5 (LAT1) synergistically with cholesterol. Sci Rep. 2020; 10(1):16738. PMC: 7541457. DOI: 10.1038/s41598-020-73757-y. View